创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

ZHANG Congyi, MU Yuan, LI Zhenhai, WANG Xinyue, CAI Wenqiu, LIU Xiaojing, ZOU Qian, LI Mengwei. Research Progress of siRNA Drugs in Tumortargeted Therapy[J]. Progress in Pharmaceutical Sciences, 2024, 48(7): 548-560. DOI: 10.20053/j.issn1001-5094.2024.07.007
Citation: ZHANG Congyi, MU Yuan, LI Zhenhai, WANG Xinyue, CAI Wenqiu, LIU Xiaojing, ZOU Qian, LI Mengwei. Research Progress of siRNA Drugs in Tumortargeted Therapy[J]. Progress in Pharmaceutical Sciences, 2024, 48(7): 548-560. DOI: 10.20053/j.issn1001-5094.2024.07.007

Research Progress of siRNA Drugs in Tumortargeted Therapy

  • Small interfering RNA (siRNA) is a new type of nucleic acid drug that plays its therapeutic roles through the RNA interference (RNAi) mechanism to target and silence the expression of target genes at the post-transcriptional level. As a precise, specific and efficient gene silencing therapy, siRNA has attracted much attention in the field of tumor-targeted therapy. Currently, several anti-tumor siRNA therapies have entered the clinical trial stage. This article summarizes the research progress of siRNA in tumor-targeted therapy in recent years, including the mechanism of action for siRNA, the recent development of anti-tumor siRNA drugs, and the optimization strategies for the in vivo delivery of siRNA drugs, aiming to provide new insights for the development and clinical application of anti-tumor siRNA drugs.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return